Progress in Acute Myelogenous Leukemia
Authors: ROBERT PETER GALE
Journal: Annals of Internal Medicine (1984)

Editorials1 November 1984Progress in Acute Myelogenous LeukemiaROBERT PETER GALE, M.D., Ph.D.ROBERT PETER GALE, M.D., Ph.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-101-5-702 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAlthough leukemia is not a common disease, it has been a model for progress in modern cancer chemotherapy. Less than 30 years ago hematologists questioned whether patients with acute myelogenous leukemia should be treated (1). In the ensuing years substantial and important advances have been made, mostly within the past 10 years. Now, 60% to 80% of patients achieve a remission with intensive induction chemotherapy (1-10). Cytarabine and daunorubicin are the most effective drugs, but thioguanine, amsacrine, and high-dose cytarabine are also useful.Once remission is achieved, the next objective is to prevent leukemic relapse; this has proved difficult. Several...References1. CROSBY W. To treat or not to treat acute granulocytic leukemia. Arch Intern Med. 1968;122:79-80. CrossrefMedlineGoogle Scholar2. GALE R. Advances in the treatment of acute myelogenous leukemia. N Engl J Med. 1979;300:1189-97. CrossrefMedlineGoogle Scholar3. GALECLINE RM. High remission-induction rate in acute myeloid leukaemia. Lancet. 1977;1:497-9. CrossrefMedlineGoogle Scholar4. WEINSTEINMAYERROSENTHALCORALCAMITTAGELBER HRDFBR. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood. 1983;62:315-9. CrossrefMedlineGoogle Scholar5. YATESGLIDEWELLWIERNIK JOP. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982;60:454-62. CrossrefMedlineGoogle Scholar6. KEATINGSMITHMCCREDIE MTK. A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer. 1981;47:2779-88. CrossrefMedlineGoogle Scholar7. PASSEMIKEMERTELSMANNGEECLARKSON SVRTB. Acute nonlymphoblastic leukemia: prognostic factors in adults with long-term follow-up. Cancer. 1982;50:1462-71. CrossrefMedlineGoogle Scholar8. REESHAYHOE JF. Treatment of acute myeloid leukaemia following remission: results of a large collaborative trial in the U.K. [Abstract]. Proc Am Soc Clin Oncol. 1984;3:190. Google Scholar9. PREISLERBRECHERBROWMAN HMG. The treatment of acute myelocytic leukemia in patients 30 years of age and younger. Am J Hematol. 1982;13:189-98. CrossrefMedlineGoogle Scholar10. MAYERWEINSTEINCORALROSENTHALFREI RHFDE. The role of intensive postindication chemotherapy in the management of acute myelogenous leukemia. Cancer Treat Rep. 1982;66:1455-62. MedlineGoogle Scholar11. FOONGALE KR. Controversies in the therapy of acute myelogenous leukemia. Am J Med. 1982;72:963-79. CrossrefMedlineGoogle Scholar12. FOONSMALLEYRIGGSGALE KRCR. The role of immunotherapy in acute myelogenous leukemia. Arch Intern Med. 1983;143:1726-31. CrossrefMedlineGoogle Scholar13. CASSILETHBEGGBENNETT PCJ. A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood. 1984;63:843-7. CrossrefMedlineGoogle Scholar14. CHAMPLINJACOBSGALE RAR. Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy. Lancet. 1984;1:894-6. CrossrefMedlineGoogle Scholar15. BELLROHATINERSLEVIN RAM. Short-term treatment for acute myelogenous leukaemia. Br Med J [Clin Res]. 1982;284:1221-4. CrossrefMedlineGoogle Scholar16. SAUTERBERCHTOLDFOPP CWM. Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet. 1984;1:379-82. CrossrefMedlineGoogle Scholar17. WOLFFMARIONSTEIN SJR. High-dose (HD) cytosine arabinoside (ara-c) and daunorubicin (D) for acute non-lymphocytic leukemia (ANLL) in first remission [Abstract]. J Clin Oncol. 1984;3:193. Google Scholar18. GLUCKSBERGCHEEVERFAREWELLFEFERTHOMAS HMVAE. Intensification therapy for acute nonlymphoblastic leukemia in adults. Cancer. 1983;52:198-205. CrossrefMedlineGoogle Scholar19. THOMASBUCKNERCLIFT ECR. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med. 1979;301:597-9. CrossrefMedlineGoogle Scholar20. GALEKAYRIMMBORTIN RHAM. Bone marrow transplantation for acute myelogenous leukaemia in first remission. Lancet. 1982;2:1006-9. CrossrefMedlineGoogle Scholar21. FORMANSPRUCEFARBSTEIN SWM. Bone marrow ablation followed by allogeneic grafting during first complete remission of acute nonlymphocytic leukemia. Blood. 1983;61:439-42. CrossrefMedlineGoogle Scholar22. SANTOSTUTSCHKABROOKMEYER GPR. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347-53. CrossrefMedlineGoogle Scholar23. ZWAANHERMANSBARRETTSPECK FJAB. Bone marrow transplantation for acute nonlymphocytic leukaemia: a survey of the European Group for Bone Marrow Transplantation (E.G.B.M.T.). Br J Haematol. 1984;56:645-53. CrossrefMedlineGoogle Scholar24. DINSMOREKIRKPATRICKFLOMENBERG RDN. Allogeneic bone marrow transplantation for patients with acute nonlymphocytic leukemia. Blood. 1984;63:649-56. CrossrefMedlineGoogle Scholar25. KERSEYRAMSAYKIM JNT. Allogeneic bone marrow transplantation in acute nonlymphoblastic leukemia: a pilot study. Blood. 1982;60:400-3. CrossrefMedlineGoogle Scholar26. THOMASHUTCHINSON EF. Marrow transplant for acute nonlymphoblastic leukemia in first remission: a follow-up [Letter]. N Engl J Med. 1983;308:1539-40. CrossrefMedlineGoogle Scholar27. GALECHAMPLIN RR. Bone marrow transplantation in leukemia: critical analysis and controlled clinical trials. In: GALE RP, ed. Recent Advances in Bone Marrow Transplantation. New York: A.R. Liss; 1983:71-94. Google Scholar28. POWLESMORGENSTERNCLINK RGH. The place of bonemarrow transplantation in acute myelogenous leukaemia. Lancet. 1980;1:1047-50. CrossrefMedlineGoogle Scholar29. APPELBAUMDAHLBERGTHOMAS FSE. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlympohblastic leukemia: a prospective study. Ann Intern Med. 1984;101:581-8. LinkGoogle Scholar30. DINSMORESHANKKAPOOR RBN. A randomized trial of marrow transplantation vs. chemotherapy maintenance for acute myelogenous leukemia in first remission: preliminary results [Abstract]. Exp. Hematol. 1981;9:125. Google Scholar31. GALE R. A prospective controlled trial of bone marrow transplantation vs. chemotherapy in acute myelogenous leukemia [Abstract]. Blood. 1981;58:173a. Google Scholar32. POWLESWATSONMORGENSTERNKAY RJGH. Bone-marrow transplantation in leukaemia remission [Letter]. Lancet. 1982;1:336-7. CrossrefMedlineGoogle Scholar33. GALECHAMPLIN RR. How does bone marrow tranplantation cure leukaemia? Lancet. 1984;1:28-30. CrossrefGoogle Scholar34. O'KUNEWICKMEREDITH JR eds. Graft-versus-leukemia in Man and Animal Models. Boca Raton, Florida: CRC Press Inc.; 1981. Google Scholar35. WEIDENFLOURNOYTHOMAS PNE. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1989;300:1068-73. CrossrefGoogle Scholar36. MCINTYREGALE RR Graft-versus-leukemia in man. In: O'KUNEWICK JP, MEREDITH RF, eds. Graft-Versus-Leukemia. Boca Raton, Florida: CRC Press Inc.; 1981;1-9. Google Scholar37. WEIDENSULLIVANFLOURNOYSTORBTHOMAS PKNRE. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529-32. CrossrefMedlineGoogle Scholar38. MITSUYASUCHAMPLINHO RRW. Prospective randomized controlled trial of ex-vivo treatment of donor bone marrow with monoclonal anti-T cell antibody and complement for prevention of graft-versus-host disease: a preliminary report. Transplant Proc. (In press). Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byStatistics and the Great PerskyImproving Survival in Acute Myeloid Leukemia: Pick the Best Subjects?Allogeneic and autologous bone marrow transplantation for acute leukemia and malignant lymphoma: Current statusHigh‐Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer*High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Breast CancerSurvival in 86 patients, aged 15-60, with primary acute myelogenous leukemia, treated with a common program in the Norwegian health regions I, III, IV and V in the period 1990-1995Leucémie aiguë myéloblastique compliquée d'un SDRA et d'une atteinte diaphragmatiqueThe duke afm program intensive induction chemotherapy for metastatic breast cancerOverexpression of theMDRL gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-ASerum Lactate Dehydrogenase Fails to Predict Response to Treatment and Survival in Acute Non-lymphocytic LeukemiaTRANSPLANT OR CHEMOTHERAPY IN ACUTE MYELOGENOUS LEUKAEMIALow-dose cytosine arabinoside in acute non-lymphoblastic leukemiaRadiotherapy, Chemotherapy and Hormonal Therapy in the Management of Cancer Pain: Putting Patient, Prognosis, and Oncologic Options in PerspectivePost-Remission Therapy in Acute Myeloblastic Leukemia a randomized trial comparing early consolidation plus maintenance versus maintenance therapy aloneLow dose cytosine arabinoside in the treatment of myeloid leukaemias and myelodysplastic syndromesConditioning RegimensSurvival in acute myeloblastic leukemia is not prolonged by remission maintenance or early reinduction chemotherapyKinetics of daunomycin in leukemia cells and leukocytes in vivo in the ratRole of maintenance chemotherapy in acute promyelocytic leukemiaA Comparison of Cytokinetically Based Versus Intensive Chemotherapy for Childhood Acute Myelogenous LeukemiaEarly intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemiaPotentially curable neoplasmsTotal Body Irradiation and Bone Marrow Transplantation in Adelaide – A Short Report on 7 Years ExperienceAutologous bone marrow transplantation (ABMT) for acute leukaemia in complete remission: a pilot study of 33 casesQuantitative evaluation of intracellular uptake of daunorubicin in acute myeloid leukemia: A method analysisRESULTS OF CHEMOTHERAPY FOR UNSELECTED PATIENTS WITH ACUTE MYELOBLASTIC LEUKAEMIA: EFFECT OF EXCLUSIONS ON INTERPRETATION OF RESULTSMyeloblastic Leukemia: A Randomized TrialJ. ESTAPE, J.M. RODRIGUEZ FERNANDEZ, P. SANTABARBARA 1 November 1984Volume 101, Issue 5Page: 702-705KeywordsAcute myeloid leukemiaCancer chemotherapyChemotherapyDrugsHematology and oncologyThioguanine Issue Published: 1 November 1984 PDF downloadLoading ...